Stock GUFICBIO GUFIC BIOSCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gufic Biosciences Limited NSE India S.E.

Equities

GUFICBIO

INE742B01025

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:48 2024-05-03 am EDT 		5-day change 1st Jan Change
322.2 INR -2.36% Intraday chart for Gufic Biosciences Limited -1.57% +1.82%
Apr. 25 Gufic Biosciences Limited Approves Reconstitution of Various Committees CI
Apr. 04 Gufic Biosciences Forms New Wholly-Owned Arm in Dubai MT

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 8,373 5,919 3,670 8,896 24,129 18,095
Enterprise Value (EV) 1 9,133 6,860 4,831 9,449 24,657 21,151
P/E ratio 52.3 x 27 x 16.1 x 25.1 x 25.2 x 22.7 x
Yield 0.05% 0.07% 0.11% 0.09% 0.04% 0.05%
Capitalization / Revenue 2.78 x 1.69 x 1.03 x 1.82 x 3.1 x 2.62 x
EV / Revenue 3.03 x 1.96 x 1.35 x 1.94 x 3.16 x 3.06 x
EV / EBITDA 23.9 x 14.9 x 11.5 x 11.8 x 17.3 x 16.2 x
EV / FCF -38.9 x -33.4 x -26.2 x 17.9 x -135 x -9.07 x
FCF Yield -2.57% -2.99% -3.81% 5.6% -0.74% -11%
Price to Book 15.6 x 7.86 x 3.83 x 6.39 x 8.97 x 5.2 x
Nbr of stocks (in thousands) 77,350 77,830 77,830 77,830 96,945 96,945
Reference price 2 108.2 76.05 47.15 114.3 248.9 186.6
Announcement Date 9/6/18 9/6/19 10/20/20 8/28/21 8/10/22 5/29/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 3,010 3,508 3,578 4,877 7,792 6,906
EBITDA 1 381.4 459.4 418.7 803.8 1,425 1,307
EBIT 1 338.7 413.4 365.2 676.5 1,286 1,153
Operating Margin 11.25% 11.78% 10.21% 13.87% 16.5% 16.7%
Earnings before Tax (EBT) 1 295.4 353.5 303.3 577.1 1,268 1,067
Net income 1 160.2 219.4 228.6 442.3 958.4 797
Net margin 5.32% 6.26% 6.39% 9.07% 12.3% 11.54%
EPS 2 2.070 2.819 2.937 4.560 9.886 8.220
Free Cash Flow 1 -234.6 -205.1 -184.3 529 -183 -2,332
FCF margin -7.79% -5.85% -5.15% 10.85% -2.35% -33.76%
FCF Conversion (EBITDA) - - - 65.8% - -
FCF Conversion (Net income) - - - 119.59% - -
Dividend per Share 2 0.0500 0.0500 0.0500 0.1000 0.1000 0.1000
Announcement Date 9/6/18 9/6/19 10/20/20 8/28/21 8/10/22 5/29/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 760 941 1,162 553 528 3,056
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.992 x 2.049 x 2.775 x 0.6884 x 0.3704 x 2.339 x
Free Cash Flow 1 -235 -205 -184 529 -183 -2,332
ROE (net income / shareholders' equity) 35.3% 33.9% 26.7% 29.2% 43.3% 25.8%
ROA (Net income/ Total Assets) 10.2% 9.98% 7.18% 10.6% 17.6% 10.4%
Assets 1 1,569 2,198 3,183 4,182 5,447 7,644
Book Value Per Share 2 6.920 9.680 12.30 17.90 27.80 35.90
Cash Flow per Share 2 0.4700 0.4700 0.5400 0.6400 1.200 2.950
Capex 1 81.1 131 401 142 888 1,876
Capex / Sales 2.69% 3.73% 11.21% 2.91% 11.4% 27.16%
Announcement Date 9/6/18 9/6/19 10/20/20 8/28/21 8/10/22 5/29/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GUFICBIO Stock
  4. GUFICBIO Stock
  5. Financials Gufic Biosciences Limited